4 in 1 Combination Pill Receives USFDA Approval for HIV Treatment

by Reshma Anand on  November 6, 2015 at 6:53 PM AIDS/HIV News   - G J E 4
Gilead Sciences company has received approval from the Food and Drug Administration for its combination pill called Genvoya for the treatment of HIV.
4 in 1 Combination Pill Receives USFDA Approval for HIV Treatment
4 in 1 Combination Pill Receives USFDA Approval for HIV Treatment

Genvoya is a combination of its already three HIV drugs called Vitekta, Tybost and Emtriva which has the active ingredient tenofovir alafenamide. The drug gets into cells where HIV copies itself reducing drug levels in the bloodstream and with that, side effects including kidney damage and reduced bone density.

‘Genvoya, a new HIV drug has received a black box warning from the FDA as it causes severe liver problems, active acidosis and nausea. It must not be given with other antiretroviral products.’
It is administered once a day and may cause some side effects like nausea, severe liver problems and a dangerous buildup of lactic acid in the blood. Therefore FDA has given its black box warning for the drug.

"While exceptional progress has been made in the field of HIV, there is still a need for new treatment options that may help improve the health of people as they grow older with the disease," said John C. Martin, Gilead CEO.

The drug has been approved for patients aged 12 and older who have never taken HIV medicines, and for adult patients whose HIV had been suppressed by other treatments for at least six months. Genvoya should not be given with other antiretroviral products and may have drug interactions with a number of other commonly used medications.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like